Do you have any thoughts on this one? I like that they are going after a fairly novel target and there is already some clinical PoC from both MNLO and a few private competitors in these indications. That said, I'll probably just watch for now as fully-diluted market cap looks to be around $700M. I listened to their Retail Roadshow presentation (thanks ghmm) and thought it was well done.